E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
diabetes mellitus type 2, inadequate metabolic control, indication for insulin therapy myocardial lipid accumulation and left-ventricular function, retinal changes, microabluminuria, beta-cell-function, endothelial dysfunction |
Diabetes mellitus Typ 2,unzureichende Stoffwechselkontrolle, Indikation für Insulintherapie Myokardiale Lipidakkumualtion und Herzfunktion, retinale Veränderungen, Mikroalbuminurie, Beta-Zell-Funktion, Ednotheliale Dysfunktion |
|
E.1.1.1 | Medical condition in easily understood language |
Typ 2 Diabetes, bad metabolic control, need for insulin therapy acute secondary diabetes-related complications |
Typ 2 Diabetes, schlechte Stoffwechseleinstellung, insulinpflichtig akute Folgeerkrankungen |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012607 |
E.1.2 | Term | Diabetes mellitus inadequate control |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012689 |
E.1.2 | Term | Diabetic retinopathy |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012654 |
E.1.2 | Term | Diabetic complications cardiovascular |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012647 |
E.1.2 | Term | Diabetic cardiomyopathy |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012658 |
E.1.2 | Term | Diabetic complications renal |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10012657 |
E.1.2 | Term | Diabetic complications ophthalmic |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054044 |
E.1.2 | Term | Diabetic microangiopathy |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10012653 |
E.1.2 | Term | Diabetic complications |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the current study is to evaluate the acute effects of gradual, insulin sparing (GLP-1-based therapy) versus acute (insulin-based therapy) glucose lowering on myocardial lipid content (assessed by MR-spectroscopy) in patients with type 2 diabetes. |
Ziel dieser Studie ist festzustellen, ob eine alternative Insulin-sparende GLP-1 basierte Therapie im Gegensatz zu einer konventionellen Insulintherapie eine akute Zunahme des myokardialen Lipidgehaltes ("Herzverfettung") verhindern kann. |
|
E.2.2 | Secondary objectives of the trial |
Changes in • hepato-cellular lipid content • left ventricular function (ejection fraction, end-systolic volume, end-diastolic volume, stroke volume, cardiac output, mass, wall thickness, E/A-ratio) and remodeling-indices • retinal morphology, perfusion and function as measured by Optical Coherence Tomography (SD-OCT) and fluorescein angiography • retinal function measured by microperimetry • biomarkers of endothelial dysfunction • microalbuminuria • beta-cell-function
|
Veränderungen • des hepatozellulären Lipidgehaltes • der linksventrikulären Funktion (Auswurffraktion, end-systolisches und end-diastolisches Volumen, Herz-Minuten-Volumen, myokardiale Wanddicke und Remodelling-Indixes • des Augenhintergrunds (Perfusion und Funktion, vaskuläre Veränderungen) • Biomarker der endothelialen Dysfunktion • Microalbuminurie • beta-cell-function |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Type 2 diabetes • Currently under oral glucose lowering medication • Insufficient metabolic control: HbA1C > 8% • Patient understands study procedure and gives written informed consent
|
- Diabetes mellitus Typ 2 - dzt.orale antidiabetische Therapie - Unzureichende Stoffwechseleinstellung: HbA1C > 8% - PatientIn versteht die studienbezogenen Maßnahmen und gibt sein/ihr schriftliches Einverständnis |
|
E.4 | Principal exclusion criteria |
• Age < 18 years • Type 1 Diabetes, LADA-Diabetes • Prior insulin administration/therapy • Therapy with thiazolidiones • Known cardiovascular disease (history of myocardial infarction, stroke etc) • Severe arterial hypertension • Acute or chronic inflammatory disease within 2 weeks prior the study • Kidney or liver disease • Psychiatric disorder • Tendency towards claustrophobia • metal devices or other magnetic material in or on the subjects body which will be hazardous for NMR investigation
|
• Alter < 18 Jahre • Typ 1 Diabetes, LADA-Diabetes • Frühere Insulin Administration/Therapie • Therapie mit Thiazolidionen (Pioglitazon) • Bekannte koronare Herzkrankheit (Z.n.Herzinfarkt oder Schlaganfall) • Schwere arterielle Hypertonie • Akute oder chronische Infektion • Leber- oder Nierenfunktionseinschränkung • Psychiatrische Erkrankung • Klaustrophobie • Metallische Gegenstände im oder am Körper (Kotraindikation gegen MR-Untersuchung)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Changes in myocardial lipid content (assessed by MR-spectroscopy)
|
Veränderungen d. myokardialen Lipidgehalts (erhoben via MR-Spektroskopie)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
study day 28 |
28.Studientag |
|
E.5.2 | Secondary end point(s) |
Changes in: - left-ventricular function - retinopathy - microalbuminuria - beta-cell-function - biomarkers of endothelial dysfunction |
Veränderungen d.: - linksventrikulären Funktion - Augenhintergrundes - Mikroalbuminurie - Beta-Zell-Funktion - Biomarker der endothelialen Dysfunktion |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
study day 28 |
28. Studientag |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
prevention of acute secondary complications |
Prävention akuter Sekundärkomplikationen |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
konventionelle Insulintherapie |
conventionel insulin therapy |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Trial end is scheduled for June, 30th 2014 (last patient visit). |
Der letzte Studientag ist für den 30.06.2014 terminisiert. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |